Skip to content
2000
Volume 4, Issue 1
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

The design, synthesis and evaluation of several dual PPARα/γ agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPARα/β agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/157018007778992883
2007-01-01
2025-06-11
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/157018007778992883
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test